Johnson & Johnson Raises Full-Year Outlook After Strong Q2 Performance
Johnson & Johnson reported better-than-expected second-quarter results, with revenue of $25.3 billion and adjusted EPS of $2.90, leading to an upward revision in its full-year 2026 outlook. The company attributed the growth primarily to strong performance from Innovative Medicine segment products such as TREMFYA and new launches like ICOTYDE.
Topics: biotech dividend_strategy innovative_medicine pharmaceuticals